Impacts

A TIA facility will play an important role in The University of Queensland’s research to take a second-generation molecular clamp vaccine to a proof-of-concept human

Professor Paul Stupple has been appointed the Director of TIA’s Australian Translational Medicinal Chemistry Facility (ATMCF), bringing more than 20 years of experience in the

Infrastructure and expertise supported by Phenomics Australia and Therapeutic Innovation Australia (TIA) are used in fighting food poisoning toxins. The challenge: Food poisoning is estimated

The National Research Infrastructure system, embodied as a broad set of Commonwealth investments through NCRIS, is a systemic enabler of the nation’s innovation system and

TIA facilities are contributing to research programs at the Walter and Eliza Hall Institute of Medical Research (WEHI) to develop a combination medicine that can

TIA facilities are core to research into a targeted therapeutic to overcome sepsis, a leading cause of death in hospital intensive care units. TIA’s Australian

People with pain rely heavily on opioid medications, causing side effects and leading to addiction in as many as 18 million people around the world

Researchers are building on the University of Queensland’s expertise in vaccine technology and accessing TIA capabilities to develop vaccines suitable for both pandemic viruses and

Melbourne-based oncology company Prescient Therapeutics Limited (ASX: PTX) is using TIA facilities to develop a modular cell-based therapy, like LEGO, to treat cancers which can